MONTREAL--(BUSINESS WIRE)--Jan. 10, 2006--Privately held Caprion Pharmaceuticals Inc. announced today that it has entered into an agreement with ImClone Systems Incorporated (NASDAQ: IMCL) under which ImClone Systems may license certain antibody protein targets for the development of therapeutic products to treat cancer and other indications. Caprion will contribute a selection of cancer targets that it has discovered using its proprietary CellCarta(R) proteomics technology platform. ImClone Systems will have exclusive, worldwide rights to develop and commercialize therapeutics against any target it selects.
